Ankyra is developing a novel approach for cancer treatment called Anchored Immunotherapy, promoting prolonged immune activation locally while limiting systemic toxicity.
External link for Ankyra Therapeutics
Ankyra Therapeutics reposted this
Come see Ankyra Therapeutics Trial in Progress poster, A phase 1, open-label, dose escalation study on the safety and tolerability of ANK-101 in advanced solid tumors, at 9am CDT located at 158A #ASCO https://lnkd.in/ecSv2fxn
Come see Ankyra Therapeutics Trial in Progress poster, A phase 1, open-label, dose escalation study on the safety and tolerability of ANK-101 in advanced solid tumors, at 9am CDT located at 158A #ASCO https://lnkd.in/ecSv2fxn
Ankyra Therapeutics President and CEO will be the featured speaker at Drug Discovery News upcoming webinar about Combination therapy for Cancer on April 18, 2024 at 1pm ET https://lnkd.in/exKhS5NZ
Ankyra Therapeutics has announced an exclusive licensing agreement for JEN-001 with Jenga Biosciences. https://lnkd.in/eXsQxYd2
Ankyra Therapeutics is excited to announce the first patient has been dosed in our Phase 1 clinical trial evaluating ANK-101, an Anchored Immune Medicine, for the treatment of solid tumors. Read more in the press release: https://rb.gy/n6vaw7
The Ankyra Therapeutics team proudly participated in the Life Science Cares Boston #Holidayhelpers program this holiday season.
This month, results from a preclinical study demonstrating potent anti-tumor activity of our lead program ANK-101 were published in the December issue of The Journal of Clinical Investigation Insight. Data from the study on ANK-101, a novel tumor-directed anchored immune medicine (AIM), demonstrated retention at the tumor site for approximately four weeks, overcoming the challenges of intratumoral injection. To read more and to view the paper, "Intratumoral aluminum hydroxide-anchored IL-12 drives potent antitumor activity by remodeling the tumor microenvironment": https://lnkd.in/euwp_NEF
We are delighted to announce a clinical trial supply agreement with Regeneron to evaluate our lead asset, ANK-101, in combination with the anti-PD-1 therapy Libtayo® (cemiplimab). In PD-1-refractory models, ANK-101, an anchored immune medicine that has demonstrated monotherapy anti-tumor activity, has shown improved therapeutic potential when combined with PD-1 blockade. Read more: https://lnkd.in/eh9eAFu7 #immunooncology #anchoredimmunotherapy
Tomorrow, November 4, we will share additional preclinical data on mANK-101, a novel anchored immunotherapy for the treatment of cancer, in murine models during the Society for Immunotherapy of Cancer (SITC) Meeting. As we head into the clinic, these are promising preclinical results for ANK-101, not only as a monotherapy but also in combination with chemotherapy and immune checkpoint blockade. Read more: https://lnkd.in/gsYju7Ya #sitc2023 #immunooncology #cancerresearch #anchoredimmunotherapy
Today marks a milestone in our mission to transform cancer treatment through anchored immunotherapy: The U.S. Food and Drug Administration (FDA) and Health Canada have cleared our Investigational New Drug (IND) application for ANK-101, enabling us to enroll patients in our Phase I dose-escalation study evaluating the safety and tolerability of ANK-101 in solid tumors. By anchoring to and being retained at the tumor site, ANK-101 has the ability to avoid hallmark challenges of both systemic and intratumoral therapies, effectively training the body to potently destroy cancer cells. We look forward to bringing this new approach to those who need it most. Read more: https://lnkd.in/euVHR4bT #biotech #INDapproval